Literature DB >> 23679015

Epidemiology of chronic inflammatory neuropathies in southeast England.

M Mahdi-Rogers1, R A C Hughes.   

Abstract

BACKGROUND AND
PURPOSE: There is little information about the prevalence and disease burden of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN) and paraproteinaemic demyelinating neuropathy (PDN).
METHODS: Multiple sources were used to study the prevalence and clinical features of these diseases in a southeast England population of 3,557,352 people.
RESULTS: The crude prevalences were as follows: CIDP, 2.84 (95% CI 2.31-3.45); MMN, 0.53 (95% CI 0.32-0.83); and PDN, 1.04 (95% CI 0.73-1.43) per 100,000 population. All three diseases were more common in men than in women. The peak decade of onset was older in those with CIDP (70-79 years) and PDN (70-79 years) than in those with MMN (50-59 years). Disability was greater in CIDP and PDN, with median (range) overall neuropathy limitations scores of 4 (0-8) and 4 (1-6), respectively, than in MMN, with a score of 2 (1-5).
CONCLUSION: The common forms of chronic inflammatory neuropathy cause a considerable disease burden in the community.
© 2013 The Author(s) European Journal of Neurology © 2013 EFNS.

Entities:  

Keywords:  chronic inflammatory demyelinating polyradiculoneuropathy; disability; epidemiology; multifocal motor neuropathy; paraproteinaemic demyelinating neuropathy

Mesh:

Year:  2013        PMID: 23679015     DOI: 10.1111/ene.12190

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  31 in total

Review 1.  Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Richard Ac Hughes; Man Mohan Mehndiratta; Yusuf A Rajabally
Journal:  Cochrane Database Syst Rev       Date:  2017-11-29

Review 2.  Diagnosis and treatment of chronic acquired demyelinating polyneuropathies.

Authors:  Norman Latov
Journal:  Nat Rev Neurol       Date:  2014-07-01       Impact factor: 42.937

Review 3.  The Importance of Rare Subtypes in Diagnosis and Treatment of Peripheral Neuropathy: A Review.

Authors:  Brian C Callaghan; Raymond S Price; Kevin S Chen; Eva L Feldman
Journal:  JAMA Neurol       Date:  2015-12       Impact factor: 18.302

Review 4.  Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Mohamed Mahdi-Rogers; Ruth Brassington; Angela A Gunn; Pieter A van Doorn; Richard Ac Hughes
Journal:  Cochrane Database Syst Rev       Date:  2017-05-08

Review 5.  Immune-mediated neuropathies.

Authors:  Bernd C Kieseier; Emily K Mathey; Claudia Sommer; Hans-Peter Hartung
Journal:  Nat Rev Dis Primers       Date:  2018-10-11       Impact factor: 52.329

Review 6.  Immunotherapy in Peripheral Neuropathies.

Authors:  Jean-Marc Léger; Raquel Guimarães-Costa; Cristina Muntean
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

7.  Incidence and Prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis.

Authors:  Merel C Broers; Carina Bunschoten; Daan Nieboer; Hester F Lingsma; Bart C Jacobs
Journal:  Neuroepidemiology       Date:  2019-01-22       Impact factor: 3.282

Review 8.  Diagnostic insights into chronic-inflammatory demyelinating polyneuropathies.

Authors:  Johannes J Roggenbuck; Joseph Boucraut; Emilien Delmont; Karsten Conrad; Dirk Roggenbuck
Journal:  Ann Transl Med       Date:  2018-09

Review 9.  Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Man Mohan Mehndiratta; Richard A C Hughes; Jane Pritchard
Journal:  Cochrane Database Syst Rev       Date:  2015-08-25

10.  Observer blind randomised controlled trial of a tailored home exercise programme versus usual care in people with stable inflammatory immune mediated neuropathy.

Authors:  Claire M White; Robert D Hadden; Sarah F Robert-Lewis; Paul R McCrone; Jane L Petty
Journal:  BMC Neurol       Date:  2015-08-21       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.